InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (11 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
11
T+90 hit rate
33%
T+90 mean return
+4.6%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by MASSARO GEORGE, Director. Officer active across 3 companies, notably CHARLES RIVER LABORATORIES INTERNATIONAL, INC.. Cumulatively, 18 filings have been logged. Breakdown: 0 buy · 11 sells. Total volume traded: €990k. Activity tracked since 6 May 2021. The latest transaction was filed on 15 May 2025 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Declarations18 total
35 shares@ US$136.320.6% of flowCommon StockSEC:0001127602-25-014711:0
91 shares@ US$139.951.7% of flowCommon StockSEC:0001127602-25-014486:0
123 shares@ US$234.724.0% of flowCommon StockSEC:0001127602-24-015691:0
559 shares@ US$228.4117.9% of flowCommon StockSEC:0001127602-24-015518:0
664 shares0Common StockSEC:0001127602-23-015852:0
288 shares@ US$193.437.7% of flowCommon StockSEC:0001127602-23-015523:0
575 shares0Common StockSEC:0001127602-22-014431:0
24 shares@ US$228.620.0001% mcap1.2% of flowCommon StockSEC:0001127602-22-014132:0
500 shares0Common StockSEC:0001127602-21-024662:0
500 shares0Common StockSEC:0001127602-21-024662
30 shares@ US$316.7450.0001% mcap1.7% of flowCommon StockSEC:0001127602-21-016416:0
30 shares@ US$316.7451.8% of flowCommon StockSEC:0001127602-21-016416
355 shares0Common StockSEC:0001127602-21-016111:0
355 shares0Common StockSEC:0001127602-21-016111
1,572 shares@ US$336.06250.0060% mcap97.1% of flowCommon StockSEC:0001127602-21-015816:0
1,572 shares@ US$336.062598.2% of flowCommon StockSEC:0001127602-21-015816
290 sharesCommon StockSEC:0001140361-16-046823:0
300 sharesCommon StockSEC:0001140361-16-046823:1
18 of 18 declarations
About MASSARO GEORGE
George Massaro is a Board Member at Charles River Laboratories International, Inc. As a board member, he contributes to the governance and strategy of the company, which is a global leader in preclinical and clinical research services. George brings his expertise and experience to help guide the company's strategic decisions.
